CE Mark for CTVQ and $83M placement to fund EU expansion
Filed with ASX · · 3 pages · English
Summary by 6ix AI
4DMedical Ltd. has announced that its CT:VQ™ technology has received CE Mark certification, allowing for commercial deployment in the European Union, which is a significant market for respiratory imaging. The proceeds from the placement will support the commercial launch and clinical integration of CT:VQ™ across Europe. This regulatory milestone and funding will enable 4DMedical to replicate its success in the U.S. within the European market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from 4DMedical
- CTVQ deployed at Mayo Clinic
- Update - S&P DJI March 2026 Rebalance of the All Ordinaries
- S&P DJI Announces March 2026 Quarterly Rebalance
- Appendix 4D and FY26 Half Year Report
- Response to ASX Query Letter
Later from 4DMedical
- 4DMedical receives CE Mark for CT: VQ™, enabling commercial launch across the European Union
- Insignia Financial to be removed from the S&P/ASX 200 Index
- GSK contract, UK clearance for CTVQ, and ASX 200 inclusion
- Major publication validates CTVQ for lung surgery
- CTVQ enters US Outpatient Market via SimonMed 170 sites
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical